Form 4: NeuroOne Medical Technologies CEO Reports Routine Share Disposition for Tax Withholding
Insider Transaction Report
NeuroOne Medical Technologies Corp's CEO and President, David A. Rosa, reported a disposition of 2,458 shares of common stock at $0.678 per share, primarily for tax liability, maintaining a beneficial ownership of 1,158,831 shares.
Summary
- David A. Rosa, the CEO, President, and a Director of NeuroOne Medical Technologies Corp (NMTC), reported a transaction involving the company's common stock.
- On June 30, 2025, Mr. Rosa disposed of 2,458 shares of common stock.
- The disposition was executed at a price of $0.678 per share.
- The transaction code 'F' indicates that these shares were disposed of to the issuer in payment of an exercise price or tax liability, typically for tax withholding related to equity compensation.
- Following this reported transaction, David A. Rosa beneficially owns 1,158,831 shares of NeuroOne Medical Technologies Corp common stock directly.
Sentiment
Score: 5
Explanation: The filing reports a routine disposition of shares for tax withholding purposes, which is a neutral event and does not indicate a change in the insider's investment sentiment.
Industry Context
This filing is a routine insider transaction report, common for publicly traded companies when executives receive or dispose of shares, often for tax purposes. It does not provide broader insights into industry trends or competitive landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delegation of Authority | David Rosa, CEO, President, and Director, executed a Power of Attorney on June 18, 2025, appointing Emily Johns, Ronald McClurg, Phillip Torrence, and Stephanie Swan to prepare, execute, submit, and file SEC forms (including Forms 3, 4, and 5) on his behalf. This streamlines compliance with Section 16 reporting requirements. | 06/18/2025 | Enhances efficiency and ensures timely compliance with SEC filing obligations for the reporting person. |
Related Party Transactions
- The disposition of 2,458 shares of common stock by David A. Rosa to the issuer (NeuroOne Medical Technologies Corp) for tax liability purposes is a transaction with a related party (the company itself).
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax withholding, not a market sale for cash.
Key Dates
| Date | Description |
|---|---|
| 06/18/2025 | Date David Rosa executed the Power of Attorney. |
| 06/30/2025 | Date of the reported share transaction. |
| 07/02/2025 | Date the Form 4 was signed and filed by Emily Johns, by Power of Attorney. |
Keywords
NeuroOne Medical Technologies, NMTC, David Rosa, SEC Form 4, insider transaction, share disposition, tax withholding, common stock, CEO, President
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.